RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...

Let’s start by clarifying: Botox is a brand name for the injectable treatment that is used to smooth wrinkles and fine lines between the brows and on the forehead. Because it’s been around the longest ...

“The enrollment of the first patients in the MINT trials marks an important milestone as we aim to address persistent gaps in migraine care by advancing a new neurotoxin option for patients.” MINT-E ...

The sBLA is based on a Phase 3, randomized, double-blind, placebo-controlled, multicenter 184 subject trial. The sBLA submission was supported by findings from a Phase 3 multicenter, randomized, ...

The sBLA approval was based on data from a phase 3 study evaluating Xeomin in 216 patients aged 6 to 17 years with chronic sialorrhea associated with cerebral palsy, other genetic or congenital ...

GREENSBORO, N.C. — Merz Pharmaceuticals has created two programs to provide financial assistance to patients using its drug for cervical dystonia, the company said Tuesday. The programs — the Xeomin ...

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has launched flagship products XEOMIN ® (incobotulinumtoxinA) and RADIESSE ® in China. With this expansion into the world’s ...

GREENSBORO, N.C. The Food and Drug Administration has approved a treatment for muscle spasms and twitches. Merz Pharmaceuticals announced Monday the approval of Xeomin (incobotulinumtoxinA), a ...

Please see Important Consumer Safety Information below and full Prescribing Information and Medication Guide at xeominaesthetic.com. “Are you just doing the 11s?” asked my friend Kelli over text when ...

Irvine-based drug maker Allergan Inc. has stymied, for now, a rival’s attempt to widen application of a Botox competitor to cosmetic uses. U.S. District Judge Andrew Guilford in Santa Ana issued an ...

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced that the first patients have been enrolled in two global Phase III clinical trials — MINT-E (NCT07018700 ...